Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo SmithKline Taking Soft Merger Route: Will Start With Two U.S. Heads

Executive Summary

The U.S. pharmaceutical operations of Glaxo Wellcome and SmithKline Beecham will not be combined immediately as part of the merger integration process.

You may also be interested in...



Glaxo SmithKline

Merged company will not create new global headquarters in the New York/New Jersey region as previously announced (1"The Pink Sheet" Jan. 24, p. 18). U.S. operations will instead be based out of existing companies' headquarters in Research Triangle Park, N.C. (Glaxo Wellcome) and Philadelphia (SmithKline Beecham). Sales and marketing components in the U.S. will also remain separate during the first phases of the merger process (2"The Pink Sheet" Feb. 7, p. 19)

Glaxo SmithKline

Merged company will not create new global headquarters in the New York/New Jersey region as previously announced (1"The Pink Sheet" Jan. 24, p. 18). U.S. operations will instead be based out of existing companies' headquarters in Research Triangle Park, N.C. (Glaxo Wellcome) and Philadelphia (SmithKline Beecham). Sales and marketing components in the U.S. will also remain separate during the first phases of the merger process (2"The Pink Sheet" Feb. 7, p. 19)

Glaxo Lotronex Studies May Expand Market To Men, Teens, Pediatrics

Glaxo will try to expand the Lotronex (alosetron) market to men, adolescents and children, following the Feb. 9 approval of the irritable bowel syndrome treatment for use in women whose predominant IBS symptom is diarrhea.

Related Content

UsernamePublicRestriction

Register

PS035553

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel